drugset / Trial / NCT00162916

Antidepressant Maintenance in Traumatic Brain Injury

NCT00162916

Phase 4 Unknown 21 enrolled Ontario Neurotrauma Foundation
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of the study is to explore to what extent continuing the antidepressant medication citalopram (Celexa), after depression has responded to treatment, helps prevent the return of depressive symptoms in patients with recent traumatic brain injury (TBI).

Timeline

Start
2005-05
Primary completion
2008-05
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Citalopram Small molecule 20 mg
Subject Citalopram Small molecule 40 mg

Indications